Baidu
map

Sci Signal:研究人员发现关键的促癌基因

2015-01-09 佚名 生物谷

TGF-β在癌症生物学中一直是个秘密,TGF-β如何既可以阻止癌细胞的形成,又如何刺激肿瘤积极生长。 现在,美国密歇根州综合癌症中心的研究人员已经发现一个关键基因,可以解释这种矛盾,提供潜在治疗靶标。 TGF-β是已知的肿瘤抑制因子,这意味着对于保持细胞正常生长是必要的。但在某些时候,它的功能会转换成肿瘤启动子,促进癌症发展与扩散。研究人员发现BUB1可作为参与调节TGF-β受体的一个关键基因

TGF-β在癌症生物学中一直是个秘密,TGF-β如何既可以阻止癌细胞的形成,又如何刺激肿瘤积极生长。

现在,美国密歇根州综合癌症中心的研究人员已经发现一个关键基因,可以解释这种矛盾,提供潜在治疗靶标。

TGF-β是已知的肿瘤抑制因子,这意味着对于保持细胞正常生长是必要的。但在某些时候,它的功能会转换成肿瘤启动子,促进癌症发展与扩散。研究人员发现BUB1可作为参与调节TGF-β受体的一个关键基因。

这项研究发表在Science Signaling杂志上。

BUB1是众所周知的在细胞分裂中发挥作用。但是,这是首次将Bub1与TGF-beta联系起来。我们认为,这也许可以解释TGF-β作为肿瘤启动子和抑癌因子的悖论。

密歇根大学研究人员包括Shyam Nyati博士团队开发出一种方法筛选调节TGF-β受体的基因。当对肺癌和乳腺癌细胞的人类基因组720个基因进行了筛选,BUB1发挥对TGF-β信号调控的强烈作用。

BUB1显示能结合到TGF-β受体,并允许开启侵袭性细胞的生长。当研究人员阻断BUB1,它彻底关闭TGF-β途径。TGF-β已知在侵袭性癌细胞发展中有作用,研究人员也已知道,BUB1在许多不同类型的癌症中高度表达。

因为BUB1在许多类型癌症中表达,因此靶向它开发出一种药物发现可能潜在地影响多种癌症。目前已开发出靶向BUB1的化合物,但还没有准备好在患者中开展测试。初始实验室测试表明,这种BUB1的抑制剂可以非常特异性靶向BUB1,而不会损坏细胞的其他部分。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1754022, encodeId=3a6b1e54022ff, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Tue Oct 27 21:19:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036127, encodeId=a6d8203612e54, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Feb 02 14:19:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677557, encodeId=fc0516e7557e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sun Apr 05 14:19:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793959, encodeId=26a91e939593c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Oct 28 04:19:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907437, encodeId=db2e190e43770, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun May 24 16:19:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373874, encodeId=8da013e38746b, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13940, encodeId=123813940bc, content=这两种药物的反应有所不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13941, encodeId=c0741394177, content=还是不错的文章偏, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1754022, encodeId=3a6b1e54022ff, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Tue Oct 27 21:19:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036127, encodeId=a6d8203612e54, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Feb 02 14:19:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677557, encodeId=fc0516e7557e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sun Apr 05 14:19:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793959, encodeId=26a91e939593c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Oct 28 04:19:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907437, encodeId=db2e190e43770, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun May 24 16:19:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373874, encodeId=8da013e38746b, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13940, encodeId=123813940bc, content=这两种药物的反应有所不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13941, encodeId=c0741394177, content=还是不错的文章偏, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-02-02 楚秀娟
  3. [GetPortalCommentsPageByObjectIdResponse(id=1754022, encodeId=3a6b1e54022ff, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Tue Oct 27 21:19:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036127, encodeId=a6d8203612e54, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Feb 02 14:19:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677557, encodeId=fc0516e7557e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sun Apr 05 14:19:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793959, encodeId=26a91e939593c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Oct 28 04:19:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907437, encodeId=db2e190e43770, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun May 24 16:19:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373874, encodeId=8da013e38746b, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13940, encodeId=123813940bc, content=这两种药物的反应有所不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13941, encodeId=c0741394177, content=还是不错的文章偏, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-04-05 changhe722
  4. [GetPortalCommentsPageByObjectIdResponse(id=1754022, encodeId=3a6b1e54022ff, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Tue Oct 27 21:19:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036127, encodeId=a6d8203612e54, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Feb 02 14:19:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677557, encodeId=fc0516e7557e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sun Apr 05 14:19:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793959, encodeId=26a91e939593c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Oct 28 04:19:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907437, encodeId=db2e190e43770, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun May 24 16:19:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373874, encodeId=8da013e38746b, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13940, encodeId=123813940bc, content=这两种药物的反应有所不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13941, encodeId=c0741394177, content=还是不错的文章偏, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-10-28 yaanren
  5. [GetPortalCommentsPageByObjectIdResponse(id=1754022, encodeId=3a6b1e54022ff, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Tue Oct 27 21:19:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036127, encodeId=a6d8203612e54, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Feb 02 14:19:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677557, encodeId=fc0516e7557e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sun Apr 05 14:19:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793959, encodeId=26a91e939593c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Oct 28 04:19:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907437, encodeId=db2e190e43770, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun May 24 16:19:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373874, encodeId=8da013e38746b, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13940, encodeId=123813940bc, content=这两种药物的反应有所不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13941, encodeId=c0741394177, content=还是不错的文章偏, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1754022, encodeId=3a6b1e54022ff, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Tue Oct 27 21:19:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036127, encodeId=a6d8203612e54, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Feb 02 14:19:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677557, encodeId=fc0516e7557e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sun Apr 05 14:19:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793959, encodeId=26a91e939593c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Oct 28 04:19:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907437, encodeId=db2e190e43770, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun May 24 16:19:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373874, encodeId=8da013e38746b, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13940, encodeId=123813940bc, content=这两种药物的反应有所不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13941, encodeId=c0741394177, content=还是不错的文章偏, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1754022, encodeId=3a6b1e54022ff, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Tue Oct 27 21:19:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036127, encodeId=a6d8203612e54, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Feb 02 14:19:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677557, encodeId=fc0516e7557e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sun Apr 05 14:19:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793959, encodeId=26a91e939593c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Oct 28 04:19:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907437, encodeId=db2e190e43770, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun May 24 16:19:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373874, encodeId=8da013e38746b, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13940, encodeId=123813940bc, content=这两种药物的反应有所不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13941, encodeId=c0741394177, content=还是不错的文章偏, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-01-10 zczcz6655

    这两种药物的反应有所不同

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1754022, encodeId=3a6b1e54022ff, content=<a href='/topic/show?id=a67c2e10345' target=_blank style='color:#2F92EE;'>#促癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27103, encryptionId=a67c2e10345, topicName=促癌基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82e136650243, createdName=ssnine, createdTime=Tue Oct 27 21:19:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036127, encodeId=a6d8203612e54, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Feb 02 14:19:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677557, encodeId=fc0516e7557e3, content=<a href='/topic/show?id=fa5c2e100cd' target=_blank style='color:#2F92EE;'>#促癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27100, encryptionId=fa5c2e100cd, topicName=促癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ab727554053, createdName=changhe722, createdTime=Sun Apr 05 14:19:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793959, encodeId=26a91e939593c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Oct 28 04:19:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907437, encodeId=db2e190e43770, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun May 24 16:19:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373874, encodeId=8da013e38746b, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13940, encodeId=123813940bc, content=这两种药物的反应有所不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13941, encodeId=c0741394177, content=还是不错的文章偏, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:27:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-01-10 zczcz6655

    还是不错的文章偏

    0

相关资讯

诺华开发抗衰老的灵丹妙药

据制药企业诺华公司(Novartis)报告,他们正在实验的这种药瞄准与老化和免疫功能有关的基因信号路径,能明显提高老年人免疫系统功能,有望延缓衰老对人体的影响,增进老年人健康。 这种实验性药物是雷帕霉素(rapamycin)的一个版本,能使老年人对流感疫苗的免疫反应提高20%。雷帕霉素属于一类叫做mTOR(哺乳动物雷帕霉素靶蛋白)抑制剂的药物,在小鼠和其他动物身上的实验证明,它有抗衰老及衰老

诺华治疗肢端肥大症长效药物获得FDA批准

美国FDA最近批准了诺华公司开发的用于治疗罕见疾病肢端肥大症的生长激素类药物Signifor登陆美国市场。这一药物也是继Sandostatin后,诺华公司在该领域开发的另一种主打产品。Sandostatin于今年失去专利保护。因此,诺华公司希望Signifor的批准能够填补公司在这一市场上的空白。 Signifor是一种肌肉注射用药物,这种药物能够结合患者体内的生长激素抑制素受体,进而下调患

测序巨头公司 15亿美元建生命科学园

近日,BioMed房产信托公司宣布:世界测序巨头Illumina公司签署协议,在福斯特市租下360000平方英尺的场地,创建最先进的生命科学园区,租期为15年。这项租地协议是过去十年里,生命科学领域最大的一笔租赁交易。有媒体透露该园区建设将耗资15亿美元。 新园区将包括:实验室大楼区和办公楼区,共计360000平方英尺,一期工程占地200000平方英尺,预计2017交付使用。众多的设施中,还

史上强大基因检测测评:Francis S. Collins写的23andMe,deCODE,Navigenics测评

  很多人都知道Francis S. Collins是“国际人类基因组计划”的首席科学家,美国国立卫生研究院(NIH)的院长,少有人知道他还是有执照的医生,更少有人知道,还是一个作家,他在2011年出版的《The Language of Life: DNA and the Revolution in Personalized Medicine》(生命的语言:DNA和个体化医学革命)

2014年FDA批准新药 抗肿瘤领域有9只药物获批

2014年美国FDA药品评价和研究中心(CDER)批准了41个新分子实体(NME)和生物制品许可申请(BLA)(不包括FDA生物制品评价与研究中心(CBER)批准的疫苗、血液制品等产品),高于2013年(27只)和2012年(39只)的新药数量。作为FDA批准药物丰硕的一年,其中抗肿瘤领域有9只药物获批,成为获得批准药物最多的领域。其次,4只糖尿病药物,4只新型抗菌药物,其中新型抗菌药物获

基因疗法:改良病毒为患者导入健康基因

所谓基因疗法,就是利用正常基因填补或替代基因疾病中某些病变或缺失的基因的治疗方法。近年来,英国牛津和美国费城的一些研究人员宣布,他们对因患有罕见基因疾病而影响视力的病人们进行了治疗,成功使他们的视力获得改善。意大利的科学家们也宣布,他们使患有另外两种基因疾病的病人病情得到了减轻。这些研究结果,以及Web of Science网站上记录的引文统计,都着眼于基因疗法中的一个类别——而它从诞生伊始,

Baidu
map
Baidu
map
Baidu
map